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Abstract
Objective
To investigate predictors of performance on a range of cognitive measures including the
Preclinical Alzheimer Cognitive Composite (PACC) and test for associations between cog-
nition and dementia biomarkers in Insight 46, a substudy of the Medical Research Council
National Survey of Health and Development.
Methods
A total of 502 individuals born in the same week in 1946 underwent cognitive assessment at age
69–71 years, including an adapted version of the PACC and a test of nonverbal reasoning.
Performance was characterized with respect to sex, childhood cognitive ability, education, and
socioeconomic position (SEP). In a subsample of 406 cognitively normal participants, asso-
ciations were investigated between cognition and β-amyloid (Aβ) positivity (determined from
Aβ-PET imaging), whole brain volumes, white matter hyperintensity volumes (WMHV), and
APOE «4.
Results
Childhood cognitive ability was strongly associated with cognitive scores including the PACC
more than 60 years later, and there were independent eﬀects of education and SEP. Sex
diﬀerences were observed on every PACC subtest. In cognitively normal participants,
Aβ positivity and WMHV were independently associated with lower PACC scores, and Aβ
positivity was associated with poorer nonverbal reasoning. Aβ positivity and WMHV were not
associated with sex, childhood cognitive ability, education, or SEP. Normative data for 339
cognitively normal Aβ-negative participants are provided.
Conclusions
This study adds to emerging evidence that subtle cognitive diﬀerences associated with Aβ
deposition are detectable in older adults, at an age when dementia prevalence is very low. The
independent associations of childhood cognitive ability, education, and SEP with cognitive
performance at age 70 have implications for interpretation of cognitive data in later life.
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Alzheimer disease (AD) has a preclinical window extending
perhaps 20 years before the onset of symptoms1 and research
criteria are increasingly using biomarkers to identify individuals
with preclinical disease.2,3 Accumulation of brain β-amyloid
(Aβ) is a very early feature of the disease process.4 There is
therefore considerable interest in identifying individuals who
are Aβ-positive (Aβ+) for recruitment to preclinical AD trials.
Emerging evidence suggests that subtle cognitive decline is
present in this preclinical phase,5 which has led to eﬀorts to
develop sensitive cognitive measures such as the Preclinical
Alzheimer Cognitive Composite (PACC)6 to detect and track
this decline. Cognitively normal Aβ+ older adults have shown
faster decline on the PACC than Aβ− individuals,7,8 but evi-
dence for cross-sectional diﬀerences on the PACC between
Aβ groups is mixed.6–12
The life course determinants of performance on the PACC in
older age are unknown. Insight 46, a substudy of the National
Survey ofHealth andDevelopment (NSHD) (British 1946Birth
Cohort), is uniquely placed to address this, since data are
available on participants’ cognition since childhood. Participants
were assessed at an age where the prevalence of dementia is low
(;3%),13 but 15%–25% are expected to be Aβ+.14
This study aimed ﬁrst to characterize the performance of
Insight 46 participants on cognitive tests including the PACC
with respect to sex, childhood cognitive ability, education, and
adult socioeconomic position. We then explored whether
cognitive performance was inﬂuenced by amyloid status,
structural MRI biomarkers including brain and white matter
hyperintensity volumes, and genetic risk for AD (APOE e4).
Methods
The NSHD is a population-based cohort of 5,362 men and
women born across mainland Britain during 1 week in March
1946. With 24 data collections across childhood and adult-
hood, most recently at age 68–69, it is the world’s longest
continuously running birth cohort.15 For the Insight 46
neuroscience substudy, 502 NSHD participants were
recruited and assessed at a clinic in University College Lon-
don between May 2015 and January 2018. Recruitment
procedures have been described previously16,17 and are
summarized in ﬁgure 1. Measures included cognitive tests,
clinical history and examination, Aβ-PET imaging, brain MRI,
and other biomarker and genetic measures as detailed
elsewhere.16 Each participant had an informant who com-
pleted the AD8 interview, a brief screening tool for
dementia.18
Standard protocol approvals, registrations,
and patient consents
The study was approved by the National Research Ethics
Service Committee London (REC reference 14/LO/1173)
and all participants provided written informed consent.
Cognitive assessment
The original PACC is composed of 4 cognitive tests: the Mini
Mental State Examination (MMSE), Logical Memory IIa from
theWechsler Memory Scale-Revised, Digit-Symbol Substitution
test (DSST) from theWechsler Adult Intelligence Scale-Revised,
and the Free and Cued Selective Reminding Test (FCSRT).6
Several variations of the PACC have been tested.6–8,19–22 We
replaced the FCSRT with the 12-item Face-Name test
(FNAME-12),23 to avoid potential overlap with a similar word-
learning memory test administered to the NSHD cohort at
multiple time-points throughout adulthood.24 FNAME-12 is
similar to FCSRT in terms of being an episodic memory test of
immediate and delayed recall, is moderately correlated with
FCSRT free recall scores23 and is also relatively challenging for
cognitively normal populations. Two previous studies have
reported that FNAME is sensitive to Aβ deposition.25,26
Participants also completed the Matrix Reasoning test from
the Wechsler Abbreviated Scale of Intelligence27—a measure
that was chosen for its similarity to aspects of the cognitive
tests completed in childhood.
The MMSE28 is a 30-point composite screening tool for cog-
nitive impairment that is widely used within clinical practice.
The DSST29 is an index of executive function and psycho-
motor speed. The score is the number of items completed
correctly within 90 seconds.
Logical Memory IIa30 assesses free recall of a short story,
which the participant is asked to recall immediately and after
a delay of approximately 20 minutes.
The FNAME-1223 assesses associative memory for face–name
and face–occupation pairs. Two versions exist: FNAME-12A
and FNAME-12B. This study used FNAME-12A. Participants
are shown 12 unfamiliar face–name and face–occupation pairs
(e.g., “Sarah, reporter”), with 8 seconds to study each one. They
Glossary
Aβ = β-amyloid;AD = Alzheimer disease;CI = conﬁdence interval;DSST =Digit Symbol Substitution Test; FCSRT = Free and
Cued Selective Reminding Test; FNAME-12 = 12-item Face-Name test; MCI = mild cognitive impairment; MMSE = Mini-
Mental State Examination; NSHD = National Survey of Health and Development; PACC = Preclinical Alzheimer Cognitive
Composite; SEP = socioeconomic position; SPM = statistical parametric mapping; SUVR = standard uptake volume ratio;
TIV = total intracranial volume; WMHV = white matter hyperintensity volume.
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are then presented with each face and asked to recall the as-
sociated name and occupation. This process is repeated with
a second learning phase and a second recall test. After a ;10-
minute delay, they are again shown each face and asked to recall
the names and occupations (the third recall test). After a;30-
minute delay, participants are shown 12 sets of 3 faces and
Figure 1 Flowchart of recruitment and data acquisition
The specific dataset refers to a set of life course data that formed the original criteria for Insight 46 eligibility. See reference 17 for further details. To reach our
target sample size, these criteriawere relaxed to remove the requirement for a previousmeasure of lung function, smoking, or physical exercise. a Inmost cases,
thiswasdue toerroneous segmentationof vascular abnormalities suchas strokeor demyelination. b These numbers addup to 54because someparticipants had
more than one condition. See Methods for details of the definitions of neurologic and psychiatric disorders. FLAIR = fluid-attenuated inversion recovery.
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asked to identify each previously learned face from the 2 dis-
tractors (facial recognition) and to recall the name and occu-
pation (the fourth recall test). If they cannot recall the name or
occupation, they are asked to select the correct answer from 3
options comprising the correct answer, a distractor (a name/
occupation that belongs with a diﬀerent face in the set), and
a name/occupation that did not feature in the set. The sum-
mary outcomes are FN-N (total names recalled, maximum 48),
FN-O (total occupations recalled, maximum 48), and
FNAME-total (FN-N + FN-O, maximum 96)—these out-
comes are based on the 4 recall tests. Precise administration
times were recorded for a sample of 50 participants to check
that the delay times conformed to expectations: the mean delay
times were 10.0 minutes and 35.5 minutes.
The Matrix Reasoning Test assesses nonverbal reasoning, an
aspect of ﬂuid intelligence. Participants are shown a matrix of
geometric shapes and are required to select the missing piece
from 5 options. There are 32matrices, graded in diﬃculty, and
the test is discontinued when participants make 4 consecutive
errors (or 4 errors within 5 consecutive items), as speciﬁed in
the manual.27
The 4 components of our version of the PACC were MMSE
total score, Logical Memory delayed recall score, DSST score,
and FNAME-total. Following the method described in
previous studies,8,11,12,19,20 the 4 components were con-
verted into z scores based on the full Insight 46 sample, and
then averaged. A higher PACC score indicates better per-
formance. Two participants did not complete the FNAME
test and one did not complete the DSST. For these 3 par-
ticipants, their PACC score was the average of the z scores
for the 3 tests they completed. This is consistent with
a previous study that required at least 2 out of the 4 com-
ponents to be present.10 Excluding these 3 people did not
change any of the results.
Life course and clinical variables
Childhood cognitive ability was measured at age 8 using 4
tests of verbal and nonverbal ability devised by the National
Foundation for Education Research.31 The sum of scores
from these 4 tests was standardized into a z score representing
overall cognitive ability. If these data were missing, the
equivalent score from the tests at age 11 was used (or if this
was missing, the score from age 15 was used). These stan-
dardized scores were based on the full NSHD cohort.
Educational attainment was represented as the highest edu-
cational or training qualiﬁcation achieved by age 26, grouped
into 5 categories: no qualiﬁcation, below O-levels (voca-
tional), O-levels and equivalents, A-levels and equivalents,
higher education (degree and equivalents).
Adult socioeconomic position (SEP) was derived from par-
ticipants’ own occupation at age 53, or earlier if this was
missing. Occupations were coded according to the UK Reg-
istrar General’s Standard Occupational Classiﬁcation, then
classiﬁed into 6 categories: unskilled, partly skilled, skilled
manual, skilled nonmanual, intermediate, professional.
Participants were coded as having a neurologic or major
psychiatric condition if they met any of the following criteria:
(1) clinical evidence of dementia, Parkinson disease, or other
neurodegenerative disorder; (2) psychiatric disorder re-
quiring antipsychotic medication; (3) depression requiring
electroconvulsive shock therapy; (4) epilepsy requiring active
treatment; (5) radiologic evidence of traumatic brain injury or
major neurosurgery; (6) clinical diagnosis or radiologic fea-
tures of multiple sclerosis; (7) clinical diagnosis of stroke, or
radiologic evidence of cortical ischemia or hemorrhage con-
sistent with previous cortical stroke; (8) radiologic evidence
of possible brain malignancy; (9) mild cognitive impairment
(MCI) deﬁned as follows, based on published criteria32:
1. no clinical evidence of dementia; and
2. participant concern regarding cognition (memory or
cognitive diﬃculties more than other people the same
age, or if they reported that they would seek medical
attention regarding their diﬃculties) or informant
concern regarding the participant’s cognition (AD8
score ≥2); and
3. objective evidence of either an amnestic (Logical
Memory delayed recall ≥1.5 SD below the mean) or
nonamnestic deﬁcit (DSST score ≥1.5 SD below the
mean). These cognitive tests were chosen for deﬁning
a cognitive deﬁcit on the basis of their normal distribution
across the entire sample.
Participants not meeting any of these criteria are hereafter
referred to as cognitively normal and represent a sample who
might be considered eligible for a clinical trial of cognitively
healthy individuals, free from possible confounding comor-
bidities. This does not imply that all participants with a neu-
rologic or major psychiatric condition necessarily had
a measurable cognitive impairment. Numbers of participants
in each category are detailed in ﬁgure 1.
Biomarker measures
Aβ-PET and multimodal MRI data were collected simulta-
neously during a 60-minute scanning session on a single
Biograph mMR 3T PET/MRI scanner (Siemens Healthcare,
Erlangen, Germany), with IV injection of 370 MBq of the Aβ-
PET ligand, 18F-Florbetapir (Amyvid). Protocol details have
been described elsewhere.16
Aβ deposition was quantiﬁed using a standard uptake volume
ratio (SUVR), calculated from cortical regions of interest with
a reference region of eroded subcortical white matter, using 10
minutes of static steady-state ﬂorbetapir data ;50 minutes
postinjection. A cutpoint for Aβ positivity was determined
using a mixture model to deﬁne 2 Gaussians, and using the
99th percentile of the lower (Aβ negative) Gaussian, at SUVR
>0.6104. Aβ-PET attenuation correction was performed using
pseudo-CT correction.16 Due to technical issues, only console
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attenuation correction was available for 26 participants. For
these participants, a pseudo-CT corrected value was imputed
based on the console value.
Whole brain volume was generated from high-resolution 3D
T1-weighted MRI using automated segmentation with man-
ual editing.16 Total intracranial volume (TIV) was calculated
using statistical parametric mapping (SPM) software (SPM12;
ﬁl.ion.ucl.ac.uk/spm).33 Global white matter hyperintensity
volume (WMHV) was generated from multimodal MRI using
an automated segmentation algorithm based on a multivariate
Gaussian mixture model,34 followed by visual quality control,
generating a global WMHV including subcortical gray matter
but excluding infratentorial regions.
APOE genotype was determined from DNA analysis of blood
samples as previously described16 and classiﬁed into 3 cate-
gories based on the presence of the e4 allele: no e4, e4 het-
erozygous, and e4 homozygous.
Fifty-seven participants were missing biomarker data
(ﬁgure 1).
Data analyses
To investigate the relationship between cognitive outcomes
and demographic factors we included all participants (n =
502), as we aimed to describe the predictors of cognitive
performance in as representative a sample as possible. Raw
scores from each cognitive test were standardized to z scores
based on the full Insight 46 sample to allow comparison of
eﬀect sizes across diﬀerent cognitive tests. Multivariable linear
regression models were run where the outcome was the z
score on a particular cognitive test and the predictors were sex,
age at assessment, childhood cognitive ability, education,
adult SEP, and presence of a neurologic or major psychiatric
condition (including MCI). Examination of residuals was
performed to check model ﬁts. For outcomes with skewed
distributions (MMSE and Matrix Reasoning), bootstrapping
was used to produce bias-corrected and accelerated 95%
conﬁdence intervals (CIs) from 2,000 replications. For the
Logical Memory delayed recall score, the model contained an
additional factor of delay duration (time elapsed between the
immediate and delayed recall). Mean delay duration was 24.6
minutes (SD 4.66) and there was no evidence that this was
associated with performance (regression coeﬃcient = −0.006,
95% CIs −0.024 to 0.012, p = 0.53), but it was included in the
models as per standard practice.
To investigate associations between cognitive performance
and biomarkers of brain pathology, we included only those
participants classiﬁed as cognitively normal (i.e., no dementia,
non-MCI population free from possible confounding
comorbidities), and for whom all biomarker data were avail-
able (n = 406). The z score on a particular cognitive test was
the outcome and Aβ status, whole brain volume, WMHV, and
APOE genotype were included as predictors in multivariable
regression models to examine the eﬀects of each biomarker
adjusted for all the others. To adjust for the correlation be-
tween whole brain volume and head size, TIV was included in
all models, as were the demographic and life course factors
investigated in the ﬁrst analysis (sex, age at assessment,
childhood cognitive ability, education, and adult SEP).
Interactions were investigated between amyloid status and
brain volumes, and amyloid status and WMHV.
The models were in addition rerun replacing dichotomized
amyloid status with a continuous measure of Aβ (SUVR)
to test whether increasing Aβ deposition was associated
with diﬀerences in performance. To check whether asso-
ciations between SUVR and cognition were sensitive to
the inclusion of the imputed SUVR values, the analyses
were rerun excluding the 26 participants with imputed
data.
All analyses were conducted using Stata 15 (StataCorp, Col-
lege Station, TX). Statistical signiﬁcance was set at p < 0.05.
Data availability
Anonymized data will be shared by request from qualiﬁed
investigators (skylark.ucl.ac.uk/NSHD/doku.php).
Results
Participant characteristics are reported in table 1. Descriptive
statistics for each test are given in table 2. Normative data for
cognitively normal Aβ− participants are available in table e-1
(doi.org/10.5061/dryad.nt561v7).
On average, Insight 46 participants performed at the expected
level for their age on the MMSE, DSST, and Logical Memory
tests, according to normative data.35 On theMatrix Reasoning
test, their performance (mean 24) was above the expected
level based on normative data (sample mean for 70- to 74-
year-olds is 16)27 but comparable to a sample of healthy older
adults recruited by Washington University (mean 24).36 To
date, only 2 studies have published FNAME-12 data23,37 and
Insight 46 means are higher than these.
Predictors of performance
Results of the multivariable regression models exploring
associations with demographic and life course predictors
are reported in table 3. On average, participants with neu-
rologic or major psychiatric conditions (including MCI)
scored signiﬁcantly lower on all tests (table 3). The analyses
were rerun excluding the participants with MCI to check
that these diﬀerences could not be explained by circularity
in the deﬁnition of MCI (since low scores on the Logical
Memory or DSST formed part of the MCI criteria); the
results were unchanged except that the diﬀerences were
no longer statistically signiﬁcant on MMSE and Matrix
Reasoning.
Female participants scored signiﬁcantly higher than male
participants on all measures except Matrix Reasoning (table 3);
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the greatest diﬀerence was on the FNAME-12, particularly in
recalling names.
As expected across this narrow age range (2.6 years; reﬂecting
the time it took to collect the data, since participants were all
born in the same week), there was no evidence of age eﬀects
on cognition, except on the Matrix Reasoning test, where
older age was associated with slightly poorer performance
(table 3).
Higher childhood cognitive ability was associated with better
performance on every cognitive outcome (table 3 and ﬁgure
2). Higher educational attainment and higher adult SEP were
independently positively associated with the majority of
Table 1 Participant characteristics
All participants
Cognitively normala participants with complete
biomarker datab
β-amyloid-positive β-amyloid-negative
N 502 74 332
Sex, % female 49 46 51
Age at assessment,c y, mean (SD) (range) 70.7 (0.68) (69.2 to 71.8) 70.6 (0.66) (69.4 to 71.8) 70.6 (0.70) (69.2 to 71.8)
Highest educational qualification, %
None 15.5 17.6 15.4
Below O-levels (vocational) 5.2 6.8 4.2
O-levels or equivalent 24.9 25.7 26.2
A-levels or equivalent 35.7 32.4 35.2
Degree or equivalent 18.7 17.6 19.0
Childhood cognitive ability, z score,d mean (SD) (range) 0.39 (0.74) (−1.60 to 2.50) 0.44 (0.74) (−1.37 to 2.50) 0.41 (0.74) (−1.59 to 2.47)
Adult socioeconomic position, %
Unskilled 1.0 1.4 0.6
Partly skilled 4.8 2.7 5.4
Skilled manual 9.4 9.5 9.3
Skilled nonmanual 21.3 16.2 22.0
Intermediate 52.2 55.4 51.8
Professional 11.4 14.9 10.8
Standard uptake volume ratio, median (IQR) (range) 0.55 (0.51 to 0.58) (0.45 to
0.87)e
0.67 (0.64 to 0.71) (0.61 to
0.87)
0.53 (0.51 to 0.56) (0.47 to
0.61)
White matter hyperintensity volume, cm3, median (IQR)
(range)
3.1 (1.6 to 6.8) (0.3 to 33.7)f 3.3 (1.8 to 6.8) (0.3 to 33.7) 2.9 (1.5 to 6.4) (0.3 to 32.8)
Whole brain volume, cm3, mean (SD) (range) 1,100 (99) (819 to 1,494)g 1,118 (103) (819 to 1,326) 1,098 (97) (860 to 1,494)
APOE genotype, % h
No «4 70.4 39.2 77.1
«4 heterozygous 27.0 51.4 21.7
«4 homozygous 2.6 9.5 1.2
Abbreviation: IQR = interquartile range.
a See Methods for definition.
b χ2, t tests, and rank-sum tests were used to test for differences between the β-amyloid-positive and -negative groups; the only variable with a statistically
significant difference was APOE (p < 0.0001).
c Age at assessmentwas calculated based on the date that the cognitive assessmentwas carried out (while assessmentswere typically completed on 1 day, 62
participants had to have their scans rescheduled for a later date, with a median interval of 49 days).
d Z scores for childhood cognitive ability were based on the full National Survey of Health and Development cohort of n = 5,362, so the mean for Insight 46
participants indicates that they had higher childhood cognitive ability on average than their peers not recruited to this substudy.
e n = 462 due to missing data.
f n = 455 due to missing data.
g n = 468 due to missing data.
h n = 500 due to missing data.
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cognitive outcome measures, including the PACC. Higher
educational attainment showed a notable positive association
with the Matrix Reasoning task.
All these eﬀects were maintained when excluding participants
with neurologic or major psychiatric conditions, except that
the following 2 associations were directionally but no longer
statistically signiﬁcant: Logical Memory Delayed and SEP (p
= 0.073); FNAME FN-O and education (p = 0.12).
Associations with biomarkers
Results of the multivariable regression models are reported in
table 4.
Of the cognitively normal participants with complete bio-
marker data, 18.3% were classiﬁed as Aβ+ (table 1), which is
around the expected prevalence for this age.14 There were no
statistically signiﬁcant diﬀerences between the Aβ+ and Aβ−
groups by sex, age at assessment, childhood cognitive ability,
education, adult SEP, brain volume, or WMHV (table 1). As
expected, the Aβ+ group contained a higher proportion of
APOE e4 carriers (table 1). There were no statistically sig-
niﬁcant associations between WMHV and sex, childhood
cognitive ability, education, SEP, brain volume, or APOE
genotype, but there was a weak association between older age
and greater WMHV (Spearman ρ = 0.12, p = 0.016).
On average, Aβ+ participants scored lower than Aβ− partic-
ipants on every cognitive measure (table 4 and ﬁgure 3). The
unadjusted diﬀerences were only statistically signiﬁcant for
the MMSE and Matrix Reasoning (ﬁgure 3A), but in the
multivariable model adjusting for demographic, life course,
and biomarker factors, the diﬀerences were also statistically
signiﬁcant for Logical Memory immediate recall and PACC
(ﬁgure 3B and table 4).
Replacing dichotomized amyloid status with the continuous
SUVR revealed weak associations between higher SUVR and
poorer performance on MMSE (regression coeﬃcient -1.21,
95% CIs −2.39 to −0.10), Logical Memory immediate recall
(regression coeﬃcient −1.87, 95% CIs −3.22 to −0.52), and
PACC (regression coeﬃcient −1.09, 95% CIs −1.90 to
−0.29). Similar trends were observed on the other tests but
did not reach statistical signiﬁcance. These results were un-
changed when the analyses were rerun excluding the 26 par-
ticipants with imputed SUVR data.
The only outcome that showed an association with whole
brain volumewas DSST, where larger whole brain volumewas
associated with better performance (table 4).
DSST and PACC showed associations with WMHV, where
higher WMHV was associated with poorer performance
(table 4).
APOE genotype was not associated with any of the cognitive
outcomes (accounting for amyloid status and all other fac-
tors) (table 4).
There was no evidence of interactions between amyloid status
and whole brain volume, or amyloid status and WMHV.
Discussion
In this large population-based sample of older adults of ap-
proximately the same age, we investigated predictors of per-
formance on a range of cognitive measures including the
PACC. The key ﬁndings are that childhood cognitive ability
was strongly associated with all cognitive scores, signiﬁcant
sex diﬀerences in cognition were observed, and Aβ positivity
and WMHV were associated with lower PACC scores among
cognitively normal participants.
Childhood cognitive ability was consistently an important
predictor with a notable eﬀect on every cognitive outcome.
Our ﬁnding that educational attainment and adult SEP were
associated with many cognitive outcomes, independent of
childhood cognition, is consistent with previous NSHD
analyses that have shown that these factors are only moder-
ately correlated and all have direct and indirect inﬂuences on
Table 2 Descriptive statistics for each cognitive test in the
full sample (n = 502)
Mean SD Median Range
MMSE (max 30) 29.3 1.0 30 22 to 30
Matrix Reasoning (max 32) 24.0 4.9 25 4 to 32
DSSTa (max 93) 47.6 10.4 48 19 to 82
Logical Memory
Immediate (max 25) 12.8 3.5 13 4 to 22
Delayed (max 25) 11.5 3.7 12 0 to 23
FNAME-12b
FN-N (max 48) 27.0 11.7 28 0 to 47
FN-O (max 48) 38.2 8.0 40 1 to 48
Total (max 96) 65.3 18.3 67 3 to 95
Facial Recognition (max 12) 12.0 0.2 12 9 to 12
Names recognition (max
12)
10.3 1.8 11 3 to 12
Occupations recognition
(max 12)
11.6 0.9 12 4 to 12
PACC (mean of z scores) −0.00 0.73 0.07 −3.49 to
1.72
Abbreviations: DSST = Digit Symbol Substitution Test; FN-N = names recal-
led; FN-O =occupations recalled; FNAME-12 = 12-itemFace-Name test;MCI =
mild cognitive impairment; MMSE = Mini-Mental State Examination; PACC =
Preclinical Alzheimer Cognitive Composite.
a n = 501 due to missing data.
b n = 500 due to missing data.
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cognition across the life course.38,39 It is also consistent with
evidence that education and occupational attainment may have
protective eﬀects on later life cognition.40
Women are at greater risk of AD, although this may be partly
explained by greater longevity,41 and there is evidence of sex
diﬀerences in the relationships between risk factors and the
development of dementia, including APOE e4,41 lifestyle
factors,41 and childhood intelligence,42 but the relevance of
sex diﬀerences to the detection of subtle cognitive decline in
preclinical AD is unclear. The eﬀect size of sex on PACC score
was large enough to be potentially clinically meaningful (0.4
SD), suggesting that accounting for sex diﬀerences on the
PACC may be important. As the FNAME test was the com-
ponent where female participants had the greatest advantage,
versions of the PACC that include a diﬀerent memory test
may be less susceptible to sex diﬀerences.
The interpretation of the association observed between older
age at assessment and lower Matrix Reasoning score is un-
clear. While scores on this test are known to decline with age,
the eﬀect size of our association (−0.17 z score units) equates
to −0.83 points on the test per year, which is incompatible
with the much lower rate of decline across adulthood reported
by others.27,36 We considered the possibility that our result
could be explained by recruitment bias. While participants
were invited in a random order, inevitably some participants
delayed their visits due to health problems, life circumstances,
or being initially undecided about taking part. Therefore
participants tested towards the end of the data collection
period may have diﬀered in some ways from those seen ear-
lier. However, we did not ﬁnd any evidence of diﬀerences in
general health based on measures of self-rated health and
overall disease burden, as described elsewhere.17
In cognitively normal participants (i.e., excluding those who
fulﬁlled dementia or MCI criteria and those with another
neurologic or major psychiatric condition), Aβ positivity was
associated with poorer performance on the PACC. Some
previous studies have reported similar ﬁndings7 but others
have found no diﬀerence between Aβ+ and Aβ− individuals at
baseline.6,8–12 Statistically signiﬁcant diﬀerences were also
Table 3 Predictors of cognition in the full sample (n = 502)
Cognitive test
Coefficients and 95% confidence intervals for each predictor variable
R2
Sex (female
as reference)
Age at
assessment
(per year)
Education
(per
category)a
Adult SEP
(per
category)a
Childhood cognitive
ability (per z score)
Neurologic or major
psychiatric conditionb
MMSE −0.19e (−0.35
to −0.01)
−0.11 (−0.25 to
0.01)
0.15e,f (0.07 to
0.24)
0.02 (−0.08 to
0.11)
0.17e (0.05 to 0.31) −0.50e (−1.15 to −0.12) 0.12
Matrix
Reasoning
−0.14 (−0.31 to
0.03)
−0.17e,f (−0.28 to
−0.05)
0.23e,f (0.15 to
0.31)
0.12e,f (0.03 to
0.21)
0.14e,f (0.03 to 0.26) −0.32e (−0.65 to −0.05) 0.21
DSSTc −0.35e,f (−0.51
to −0.19)
−0.07 (−0.19 to
0.04)
0.16e,f (0.09 to
0.24)
0.05 (−0.05 to
0.13)
0.24e,f (0.11 to 0.36) −0.70e,f (−0.97 to −0.43) 0.20
Logical
Memory
Immediate
−0.42e,f (−0.59
to −0.26)
−0.01 (−0.13 to
0.11)
0.09e (0.01 to
0.17)
0.06 (−0.03 to
0.15)
0.29e,f (0.16 to 0.41) −0.40e (−0.67 to −0.12) 0.16
Logical
Memory
Delayed
−0.47e,f (−0.64
to −0.31)
0.02 (−0.09 to
0.14)
0.05 (−0.03 to
0.13)
0.09e (0.00 to
0.18)
0.31e,f (0.18 to 0.44) −0.59e,f (−0.86 to −0.32) 0.19
FNAME-12 FN-
Nd
−0.55e,f (−0.71
to −0.40)
−0.01 (−0.12 to
0.10)
0.08e (0.00 to
0.15)
0.12e,f (0.04 to
0.21)
0.35e,f (0.23 to 0.47) −0.47e,f (−0.74 to −0.21) 0.24
FNAME-12 FN-
Od
−0.42e,f (−0.58
to −0.26)
−0.08 (−0.19 to
0.03)
0.09e (0.01 to
0.16)
0.19e,f (0.10 to
0.28)
0.27e,f (0.15 to 0.40) −0.52e,f (−0.79 to −0.26) 0.22
FNAME-12
totald
−0.54e,f (−0.69
to −0.398)
−0.04 (−0.15 to
0.07)
0.09e (0.01 to
0.16)
0.16e,f (0.08 to
0.25)
0.34e,f (0.22 to 0.46) −0.53e,f (−0.79 to −0.27) 0.26
PACC −0.39e,f (−0.50
to −0.28)
−0.05 (−0.13 to
0.02)
0.11e,f (0.06 to
0.16)
0.08e,f (0.02 to
0.14)
0.26e,f (0.18 to 0.35) −0.60e,f (−0.78 to −0.43) 0.34
Abbreviations: DSST =Digit Symbol Substitution Test; FN-N = names recalled; FN-O = occupations recalled; FNAME-12 = 12-item Face-Name test;MMSE =Mini-
Mental State Examination; PACC = Preclinical Alzheimer Cognitive Composite; SEP = socioeconomic position.
Units are in z scores. Multivariable regression models were used so each association is independent of all others. R2 gives the proportion of variance in each
cognitive outcome that is explained by the combined predictors. Logical Memory Delayed score was in addition adjusted for time elapsed between the
immediate and delayed recall.
a See Methods for definitions of categories.
b Cognitively normal as reference category (see Methods for definitions).
c n = 501 due to missing data.
d n = 500 due to missing data.
e Significant at p < 0.05
f Significant at p < 0.01.
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observed on several individual tests assessing a range of
cognitive domains: memory (Logical Memory Immediate),
nonverbal reasoning (Matrix Reasoning), and a global mea-
sure of cognitive state (MMSE). These diﬀerences were de-
tectable despite there being diﬀerences in numbers of
participants in the Aβ+ and Aβ− groups—in line with
expectations of the proportion of Aβ+ individuals at this
age14—which reduces statistical power to detect diﬀerences
between the groups. Our results add to accumulating evidence
for subtle cognitive diﬀerences associated with Aβ deposition,
even at an age when those who are destined to develop de-
mentia are still likely to be many years from symptoms.13
In cognitively normal participants with a generally low burden
of white matter disease, we also found an independent asso-
ciation between WMHV and PACC score which, to our
knowledge, has not been reported before. This suggests that
the PACCmay be a sensitive, rather than a speciﬁc, marker of
cerebral pathology—an important consideration for clinical
trials.
Controlling for childhood cognitive ability, education and
adult SEP enabled detection of a diﬀerence in PACC score
between Aβ+ and Aβ− participants, whereas the unadjusted
group diﬀerence was not statistically signiﬁcant. This may be
partially explained by negative confounding eﬀects, whereby
one or more factors that predicted higher PACC score also
had weak positive associations with Aβ positivity. This was
indeed the case for childhood cognitive ability and adult SEP,
which were slightly higher in Aβ+ individuals (although dif-
ferences were not statistically signiﬁcant). Such diﬀerences
may well be due to chance but can suppress the association
between Aβ and cognition when not adjusted for. Another
factor may have been that adjustment for these variables re-
duced the unexplained residual variance in PACC score, thus
increasing the ability to detect smaller diﬀerences between the
groups. Accounting for IQ may be particularly important in
high-functioning individuals.43 Combined together, the de-
mographic, life course, and biomarker factors accounted for
one third of the variance in PACC score among cognitively
normal participants.
Fluid intelligence measures themselves are not usually
considered candidates for detecting subtle cognitive decline
in preclinical AD, so our ﬁnding that Aβ positivity was as-
sociated with poorer performance on the Matrix Reasoning
test, to a greater degree than the PACC (accounting for
childhood cognitive ability), is interesting. It is consistent
with evidence that nonverbal IQ declines early in pre-
symptomatic carriers of genetic mutations causing familial AD.44
As a high-level test involving multiple domains (including
visuoperceptual, working memory, and executive function),
Matrix Reasoning is rather diﬀerent from the tests comprising
the PACC, and its potential as a marker of cognitive decline
merits further investigation.
The DSST was the single test most sensitive to overall brain
health, showing associations with WMHV and whole brain
volume in cognitively normal participants, and being the task
on which participants with neurologic or major psychiatric
conditions were most disadvantaged. Negative eﬀects of
WMHV on processing speed are well-established, consistent
with subcortical damage.45 The DSST may be particularly
sensitive to brain pathologies because good performance on
this task requires multiple cognitive functions, including
visuomotor skills, executive functioning, working memory,
and attention, hence people with an impairment in any one of
these areas might perform poorly. The fact that the digit–
symbol task is timed may also contribute to its sensitivity at
detecting small diﬀerences in performance.
While some studies have reported eﬀects of APOE e4 on
cognition independent of Aβ,46 we found that cognition did
not diﬀer by APOE genotype after accounting for amyloid
status.
Few studies have published results of the FNAME test. Our
results suggest that the FNAME-12 is suﬃciently challenging
for 70-year-olds, despite scores on the occupations subscale
being somewhat skewed towards the top end. Two previous
studies found a sex diﬀerence on FNAME, which was reduced
in older adults47 and attenuated in postmenopausal women.48
Here, we found a signiﬁcant sex diﬀerence in 70-year-olds. It
has been argued that one potential beneﬁt of the FNAME test
is, in contrast to many other memory tests, its reported lack of
association with education,37 although this has been contra-
dicted in one study.23 In the current study, which beneﬁts
from prospective collection over the life course, we found that
childhood cognitive ability, education, and adult SEP were all
signiﬁcant predictors of FNAME scores.
Figure 2 Preclinical Alzheimer Cognitive Composite (PACC)
score against childhood cognitive ability
Scatterplot shows the raw data, color-coded by clinical group. Alzheimer
disease dementia is distinguished fromother neurologic ormajor psychiatric
conditions for interest. The blue line is the line of best fit from the multi-
variable regression model (adjusted for sex, age at assessment, education,
adult socioeconomic position, and presence of neurologic or major psychi-
atric conditions), and the navy lines are its 95% confidence intervals. Z scores
for childhood cognitive ability were based on the full National Survey of
Health and Development cohort (n = 5,362).
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Two previous studies reported an association between Aβ
deposition and FNAME performance, speciﬁcally on the FN-
N outcome (recall for names).25,26 While our results followed
this trend, diﬀerences between Aβ+ and Aβ− participants did
not reach statistical signiﬁcance in our sample, and the FN-N
outcome did not appear more sensitive than FN-O (recall for
occupations) or FNAME-total.
This study has a number of major strengths including the
prospective collection of clinical and demographic data
from birth, the size of the sample, and the very small age
range. All participants were from the NSHD, a country-wide
cohort of individuals born in the same week, making them
more representative than most studies in aging and de-
mentia research, which recruit convenience samples or re-
cruit through memory clinics and may be biased towards
those with higher education, higher socioeconomic status,
and better cognition.49 Insight 46 participants, however,
were required to be willing and able to attend a research visit
in London, and on average had slightly higher education and
SEP than those not in the substudy.17 Reﬂecting the general
British postwar population, all NSHD participants are
white, so they do not represent the more contemporary
ethnic and cultural diversity of the wider population. Within
Insight 46, participants with missing neuroimaging data
were more likely to be obese and to have mental health
problems.17 As obesity and depression are associated with
increased dementia risk,50 this raises the possibility that
individuals with AD pathology and associated subtle cog-
nitive decline may be underrepresented in our analyses.
Finally, the absence of tau PET imaging precluded in-
vestigation of how tau and Aβ pathology may interact to
aﬀect cognition.
These data show that childhood cognitive ability, education,
and SEP all independently inﬂuence cognitive performance at
age 70, which has implications both for the interpretation and
analysis of cognitive data measured in later life. We provide
normative data from a large cohort of Aβ-negative healthy
individuals. Our results provide evidence that the PACC can
be used to detect subtle cross-sectional diﬀerences in cogni-
tion associated with Aβ deposition and white matter disease in
cognitively normal older adults at an age where dementia
prevalence is very low.
Table 4 Associations between biomarkers and cognition in cognitively normal participants (n = 406)
Cognitive test
Coefficients and 95% confidence intervals for each predictor variable
R2
Amyloid status (Aβ2 as
reference)
WMHV (per 10
cm3)
Whole brain volume (per
10 cm3)
APOE genotype (no «4 as
reference)
«4
heterozygous
«4
homozygous
MMSE −0.24b (−0.46 to −0.02) −0.00 (−0.19 to
0.14)
−0.01 (−0.03 to 0.01) 0.10 (−0.08 to
0.28)
0.12 (−0.51 to
0.65)
0.14
DSST −0.16 (−0.40 to 0.07) −0.21b,c (−0.37 to
−0.05)
0.05b,c (0.03 to 0.07) 0.00 (−0.20 to
0.20)
−0.14 (−0.70 to
0.41)
0.21
Logical Memory
Immediate
−0.31b (−0.56 to −0.06) −0.11 (−0.27 to
0.05)
−0.01 (−0.03 to 0.01) 0.21 (−0.01 to
0.42)
0.46 (−0.12 to
1.03)
0.16
Logical Memory
Delayed
−0.20 (−0.44 to 0.05) −0.12 (−0.28 to
0.04)
−0.01 (−0.03 to 0.01) 0.19 (−0.02 to
0.39)
0.29 (−0.28 to
0.86)
0.17
FNAME FN-Na −0.03 (−0.27 to 0.20) −0.06 (−0.22 to
0.10)
0.01 (−0.01 to 0.03) −0.04 (−0.27 to
0.20)
−0.25 (−0.80 to
0.31)
0.21
FNAME FN-Oa −0.16 (−0.39 to 0.07) −0.11 (−0.26 to
0.05)
0.00 (−0.02 to 0.02) 0.13 (−0.07 to
0.32)
0.20 (−0.33 to
0.73)
0.21
FNAME-totala −0.09 (−0.32 to 0.14) −0.08 (−0.24 to
0.07)
0.01 (−0.01 to 0.03) 0.03 (−0.17 to
0.23)
−0.07 (−0.60 to
0.46)
0.23
PACC −0.17b (−0.32 to −0.02) −0.10b (−0.20 to
−0.01)
0.01 (−0.01 to 0.02) 0.08 (−0.05 to
0.21)
0.04 (−0.30 to
0.39)
0.34
Matrix Reasoning −0.39b,c (−0.70 to −0.12) −0.02 (−0.19 to
0.12)
0.01 (−0.01 to 0.03) 0.14 (−0.08 to
0.35)
0.05 (−0.39 to
0.40)
0.23
Abbreviations: Aβ− = β-amyloid negative; DSST = Digit Symbol Substitution Test; FN-N = names recalled; FN-O = occupations recalled; FNAME = Face-Name
test; MMSE = Mini-Mental State Examination; PACC = Preclinical Alzheimer Cognitive Composite; WMHV = white matter hyperintensity volume.
All units are in z scores.Multivariable regressionmodels were used so each association is independent of all others. R2 gives the proportion of variance in each
cognitive outcome that is explained by the combined predictors. Coefficients were adjusted for total intracranial volume, sex, age at assessment, childhood
cognitive ability, education, and adult socioeconomic position. LogicalMemory Delayed scorewas also adjusted for time elapsed between the immediate and
delayed recall.
a N = 405 due to missing data.
b Significant at p < 0.05.
c Significant at p < 0.01.
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